Skip to main content
Top
Published in: The Patient - Patient-Centered Outcomes Research 6/2022

Open Access 01-11-2022 | Systematic Review

The Impact of Patient Support Programs in Europe: A Systematic Literature Review

Authors: José Antonio Sacristán, Esther Artime, Silvia Díaz-Cerezo, Marta Comellas, Lucía Pérez-Carbonell, Luis Lizán

Published in: The Patient - Patient-Centered Outcomes Research | Issue 6/2022

Login to get access

Abstract

Background and Objective

Patient support programs aim to provide solutions beyond the medication itself, by enhancing treatment adherence, improving clinical outcomes, elevating patient experience, and/or increasing quality of life. As patient support programs increasingly play an important role in assisting patients, numerous observational studies and pragmatic trials designed to evaluate their impact on healthcare have been conducted in recent years. This review aims to characterize these studies.

Methods

A systematic literature review, supplemented by a broad search of gray literature, was conducted following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and Cochrane recommendations. Observational studies and pragmatic trials conducted in Europe to evaluate the impact of patient support programs, published in English or Spanish between 17/03/2010 and 17/03/2020, were reviewed. Two patient support program definitions were applied starting with Ganguli et al.’s broad approach, followed by the European Medicines Agency definition, narrowed to Marketing Authorization Holders organized systems and their medicines. The quality of publications was assessed using the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) statement 22-item checklist.

Results

Of the 49 identified studies following the Ganguli et al. definition, 20 studies met the European Medicines Agency definition and were reviewed. Patient support program impact was evaluated based on a wide range of methodologies: 70% assessed patient support program-related patient-reported outcomes, 55% reported clinical outcomes, and 25% reported economic impacts on health resources. Only 45% conducted a comparative analysis. Overall, 75% of the studies achieved their proposed objectives.

Conclusions

The heterogeneity of the observational studies reviewed reflects the complexity of patient support programs that are built ad hoc for specific diseases, treatments, and patients. Results suggest that patient support programs play a key role in promoting treatment effectiveness, clinical outcomes, and satisfaction. However, there is a need for standardizing the definition of patient support programs and the methods to evaluate their impact.
Appendix
Available only for authorised users
Literature
2.
go back to reference European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module VI: collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2). Vol. Revision 2. 2017. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module VI: collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2). Vol. Revision 2. 2017.
15.
go back to reference NCT 02750800. Post-marketing observational study to evaluate the incremental impact of AbbVie’s patient support program on patient reported outcomes and health resource utilization in inflammatory arthritis, psoriasis and inflammatory bowel diseases in Hungary (VALUE). Available from: https://www.clinicaltrials.gov/ct2/show/NCT02750800. [Accessed 20 Apr 2021]. NCT 02750800. Post-marketing observational study to evaluate the incremental impact of AbbVie’s patient support program on patient reported outcomes and health resource utilization in inflammatory arthritis, psoriasis and inflammatory bowel diseases in Hungary (VALUE). Available from: https://​www.​clinicaltrials.​gov/​ct2/​show/​NCT02750800. [Accessed 20 Apr 2021].
19.
go back to reference van Maren MA WC, Driessen JHM, Visser JV, de Vries F, van de Wijdeven K, Gevers S, Lems WF, Emmelot-Vonk MH, van den Bergh JPW. Two-year persistence with teriparatide improved significantly after introduction of an educational and motivational support program. Osteoporos Int 2019;30(9):1837–44. https://doi.org/10.1007/s00198-019-05052-0. van Maren MA WC, Driessen JHM, Visser JV, de Vries F, van de Wijdeven K, Gevers S, Lems WF, Emmelot-Vonk MH, van den Bergh JPW. Two-year persistence with teriparatide improved significantly after introduction of an educational and motivational support program. Osteoporos Int 2019;30(9):1837–44. https://​doi.​org/​10.​1007/​s00198-019-05052-0.
20.
go back to reference Morgan K, Lott N, Lyons M. Year 1 performance of adveva® a patient support programme (PSP) for patients taking MAVENCLAD® (Cladribine tablets). National clinical homecare association (NCHA). 2020. Morgan K, Lott N, Lyons M. Year 1 performance of adveva® a patient support programme (PSP) for patients taking MAVENCLAD® (Cladribine tablets). National clinical homecare association (NCHA). 2020.
21.
go back to reference Lyons M, Lott N, Morgan K. Year 1 performance of adveva®, a patient support programme (PSP) for patients taking MAVENCLAD® (cladribine tablets) for highly active relapsing remitting nultiple sclerosis (RRMS) in United Kingdom (UK) European committee for treatment and research in multiple sclerosis (ECTRIMS) 2019:P-1593. Lyons M, Lott N, Morgan K. Year 1 performance of adveva®, a patient support programme (PSP) for patients taking MAVENCLAD® (cladribine tablets) for highly active relapsing remitting nultiple sclerosis (RRMS) in United Kingdom (UK) European committee for treatment and research in multiple sclerosis (ECTRIMS) 2019:P-1593.
25.
go back to reference Ryan C, Middleton C, Lucas J, Hetherington J, Calimlim B. Assessing the impact of patient support programs in adalimumab-treated adults with psoriasis in Europe. J American Academy Dermatology. 2019:P-9826. Ryan C, Middleton C, Lucas J, Hetherington J, Calimlim B. Assessing the impact of patient support programs in adalimumab-treated adults with psoriasis in Europe. J American Academy Dermatology. 2019:P-9826.
26.
go back to reference Ryan C, Calimlim B, Lucas J, Skup M, Lobosco S. Assessing the impact of patient support programs on patient outcomes in adalimumab-treated patients with psoriasis in Europe. J American Academy Dermatology. 2018:P-6451.CrossRef Ryan C, Calimlim B, Lucas J, Skup M, Lobosco S. Assessing the impact of patient support programs on patient outcomes in adalimumab-treated patients with psoriasis in Europe. J American Academy Dermatology. 2018:P-6451.CrossRef
27.
go back to reference González B, Lorenzo C, Morales C, Santos M. Impacto del programa de soporte telefónico a pacientes con diabetes mellitus tipo 2 tratados con insulina glargina U300 (Plataforma TCOACH). Congreso Sociedad Española de Diabetes (SED) 2019.p. 83. González B, Lorenzo C, Morales C, Santos M. Impacto del programa de soporte telefónico a pacientes con diabetes mellitus tipo 2 tratados con insulina glargina U300 (Plataforma TCOACH). Congreso Sociedad Española de Diabetes (SED) 2019.p. 83.
Metadata
Title
The Impact of Patient Support Programs in Europe: A Systematic Literature Review
Authors
José Antonio Sacristán
Esther Artime
Silvia Díaz-Cerezo
Marta Comellas
Lucía Pérez-Carbonell
Luis Lizán
Publication date
01-11-2022
Publisher
Springer International Publishing
Published in
The Patient - Patient-Centered Outcomes Research / Issue 6/2022
Print ISSN: 1178-1653
Electronic ISSN: 1178-1661
DOI
https://doi.org/10.1007/s40271-022-00582-y

Other articles of this Issue 6/2022

The Patient - Patient-Centered Outcomes Research 6/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine